Sovateltide
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Sovateltide (development names IRL-1620 and PMZ-1620, sold in India under the brand name Tyvalzi) is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz. Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis.
Sovateltide (development names IRL-1620 and PMZ-1620, sold in India under the brand name Tyvalzi) is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz. Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374092792 under CC BY-SA 4.0; modifications have been made.